How to Sequence Therapies in Peripheral T Cell Lymphoma

Kitsada Wudhikarn, N. Nora Bennani

Research output: Contribution to journalReview articlepeer-review


Peripheral T cell lymphoma (PTCL) represents a heterogeneous group of rare lymphoproliferative disorders. Historically, there has been a lack of pathobiological understanding of PTCL. With the exception of ALK-positive anaplastic large cell lymphoma, patients with PTCL have less favorable outcomes, with most patients relapsing shortly after conventional anthracycline-containing multi-agent chemotherapy. The standard management approach for PTCL involves induction therapy followed by autologous stem cell transplantation. Patients with relapsed/refractory PTCL have dismal outcomes and limited treatment options despite the available novel agents, therefore remaining a critical unmet need. By virtue of advancement in cancer biology over the recent years, the treatment landscape of PTCL has gradually evolved from conventional chemotherapy based on solely morphological diagnosis toward more individualized therapies by integrating molecular attributes of PTCL to the traditional treatment paradigm. We are at the edge of witnessing a paradigm shift in PTCL management.

Original languageEnglish (US)
Article number74
JournalCurrent treatment options in oncology
Issue number9
StatePublished - Sep 2021


  • Autologous stem cell transplantation
  • Chemotherapy
  • Lymphoproliferative disorder
  • T cell lymphoma

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'How to Sequence Therapies in Peripheral T Cell Lymphoma'. Together they form a unique fingerprint.

Cite this